← Back to Search

Cancer Vaccine

HPV 16 TA-CIN for HPV Associated Cancer

Phase 1
Waitlist Available
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

Study Summary

This trial is testing a new cancer treatment and assessing how well it is tolerated by patients.

Eligible Conditions
  • HPV Associated Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients who successfully receive at least one intratumoral vaccination

Trial Design

1Treatment groups
Experimental Treatment
Group I: Main Vaccination ArmExperimental Treatment1 Intervention
Participants will receive the HPV 16 TA-CIN vaccine.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
557 Previous Clinical Trials
32,900 Total Patients Enrolled
Stéphanie Gaillard, MDStudy ChairSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1 Previous Clinical Trials
14 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025